Immunotherapy with Irradiated Tumour Cells and Bcg in Experimental Osteosarcoma

Larsson, Sven‐Erik; Lorentzon, Ronny; Boquist, Lennart

doi:10.3109/17453678108992134

Cited by 7 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 1970s, immunotherapy for osteosarcoma was reported by Southam et al [42], Neff and Enneking [34], and Campbell et al [5]. In the 1980s, new methods such as the use of interferons and Bacille de Calmette et Guérin were reported [22,24,36]. Another approach used antiidiotypic antibodies using T cells and liposome encapsulation [18,51,52].…”

Section: Discussionmentioning

confidence: 99%

“…This type of immunotherapy reportedly is effective for breast and prostate cancers [6,8,39]. Many groups have reported successful immunotherapy for osteosarcoma [5,15,18,20,22,24,25,33,34,36,42,51,52]. However, the ability to control metastatic lesions and local recurrence does not appear to be superior to other adjuvant treatments [2,7,13,23,29].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma

Kawano

Nishida

Nakamoto

et al. 2010

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background We previously reported a limb-salvage technique by treating tumor-bearing bone with liquid nitrogen. We also reported systemic antitumor immunity was enhanced by cryotreatment in a murine osteosarcoma (LM8) model. We therefore combined the cryotreatment of tumor with dendritic cells to promote tumor-specific immune responses. Questions/purposes We determined whether our technique could enhance systemic immune response and inhibit metastatic tumor growth in a murine osteosarcoma model. Materials and Methods To evaluate activation of the immune response, we prepared six groups of C3H mice (80 mice total): (1) excision only, (2) dendritic cells without reimplantation of the cryotreated primary tumor, (3) reimplantation of the cryotreated primary tumor alone, (4) dendritic cells combined with reimplantation of the cryotreated primary tumor, (5) dendritic cells exposed to cryotreated tumor lysates without reimplantation of the cryotreated primary tumor, and (6) dendritic cells exposed to cryotreated tumor lysates with reimplantation of the cryotreated primary tumor. We then compared and verified the activation state of each group's antitumor immunity. Results Mice that received dendritic cells exposed to cryotreated tumor lysates with reimplantation of the cryotreated primary tumor group had high serum interferon c, reduced pulmonary metastases, and increased numbers of CD8(+) T lymphocytes in the metastatic areas. Conclusions Combining tumor cryotreatment with dendritic cells enhanced systemic immune responses and inhibited metastatic tumor growth. Clinical Relevance We suggest immunotherapy could be developed further to improve the treatment of osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma

Kawano

Nishida

Nakamoto

et al. 2010

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…These reports of improved survival upon infection suggest that bacteria have the ability to activate antitumor immune responses. Larsson investigated the effects of immunotherapy using irradiated tumor cells and the Bacillus Calmette-Guerin (BCG) vaccine in a mouse model of osteosarcoma [16]. In the study, injecting irradiated tumor cells significantly prevented tumor incidence after the injection of living tumor cells, whereas BCG injection had no significant effect on osteosarcoma.…”

Section: Role Of the Immune System And Advancement In Immunotherapmentioning

confidence: 99%

Current and Emerging Targets in Immunotherapy for Osteosarcoma

Miwa

Shirai

Yamamoto

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the role of the immune system in malignancies, immunotherapies including immune modulators such as interleukin-2 and muramyl tripeptide, dendritic cells, immune checkpoint inhibitors, and engineered T cells have been utilized in patients with malignancies. Although there are limited reports of immunotherapies for osteosarcoma, immunotherapy is thought to be a promising treatment option for treating osteosarcomas. In this review, an overview of various immunotherapies for osteosarcoma is provided and their potential as adjuvant therapies is discussed.

show abstract

“…In that study, 10% of the patients with inoperable sarcoma showed tumor regression after the injection of Coley’s toxin. However, several studies have investigated various immune stimulators, including muramyl tripeptide, Bacillus Calmette-Guerin (BCG), and allogenic tumor cells, and have reported no significant improvement in patients with sarcomas [ 84 , 85 , 86 , 87 ]. In contrast, recent studies on the tumor microenvironment and antitumor immune system have contributed to the development of immunotherapy [ 88 ].…”

Section: Immunotherapymentioning

confidence: 99%

Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma

Miwa

Yamamoto

Hayashi

et al. 2020

Cancers

View full text Add to dashboard Cite

Rhabdomyosarcoma, the most common soft tissue sarcoma noted in childhood, requires multimodality treatment, including chemotherapy, surgical resection, and/or radiation therapy. The majority of the patients with localized rhabdomyosarcoma can be cured; however, the long-term outcomes in patients with metastatic rhabdomyosarcoma remain poor. The standard chemotherapy regimen for patients with rhabdomyosarcoma is the combination of vincristine, actinomycin, and cyclophosphamide/ifosfamide. In recent clinical trials, modifications of the standard chemotherapy protocol have shown improvements in the outcomes in patients with rhabdomyosarcoma. In various type of malignancies, new treatments, such as molecular targeted drugs and immunotherapies, have shown superior clinical outcomes compared to those of standard treatments. Therefore, it is necessary to assess the benefits of these treatments in patients with rhabdomyosarcoma. Moreover, recent basic and clinical studies on rhabdomyosarcoma have reported promising therapeutic targets and novel therapeutic approaches. This article reviews the recent challenges and advances in the management of rhabdomyosarcoma.

show abstract

Immunotherapy with Irradiated Tumour Cells and Bcg in Experimental Osteosarcoma

Cited by 7 publications

References 14 publications

Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma

Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma

Current and Emerging Targets in Immunotherapy for Osteosarcoma

Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma

Contact Info

Product

Resources

About